Drug Profile
Research programme: antibody-based cancer therapies - Amgen/Oxford BioTherapeutics
Alternative Names: OX 076Latest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Amgen; Oxford Genome Sciences
- Developer Amgen; Oxford BioTherapeutics
- Class Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cancer
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 28 Jun 2018 No recent reports of development identified for preclinical development in Breast-cancer in United Kingdom (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)